Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tumor test could match patients to best chemo, study finds

NCT ID NCT03217097

Completed Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

Summary

This study aimed to see if a specific marker in a tumor (called MGMT) can predict which type of chemotherapy works better for patients with advanced neuroendocrine tumors. Researchers tested 116 patients to see if those with a 'methylated' MGMT marker responded better to one class of drugs (alkylating agents), while those without it responded better to a different drug (oxaliplatin). The goal was to gather evidence to help doctors personalize the first chemotherapy choice for future patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CH Annecy Genevois

    Pringy, 74374, France

  • CHU d'Angers

    Angers, 49933, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Hôpital Beaujon - APHP

    Clichy, 92118, France

  • Hôpital Claude Hurriet - CHRU Lille

    Lille, 59037, France

  • Hôpital Cochin - APHP

    Paris, 75014, France

  • Hôpital Edouard Herriot - Hospices Civils de Lyon

    Lyon, 69003, France

  • Hôpital Estaing, CHU de Clermont-Ferrand

    Clermont-Ferrand, 63003, France

  • Hôpital François Mitterrand - CHU Dijon Bourgogne

    Dijon, 21000, France

  • Hôpital Nord - CHU Saint Etienne

    Saint-Priest-en-Jarez, 42270, France

  • Hôpital Privé Jean Mermoz

    Lyon, 69008, France

  • Hôpital Rangueil - CHU Toulouse

    Toulouse, 31059, France

  • Hôpital Robert Debré - CHU Reims

    Reims, 51092, France

  • Hôpital Saint Louis - APHP

    Paris, 75010, France

  • Hôpital Sud - CHU Amiens

    Amiens, 80054, France

  • Hôpital Trousseau - CHU Tours

    Tours, 37044, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Institut Paoli Calmettes

    Marseille, 13009, France

  • Institut de Cancérologie de la Loire

    Saint-Priest-en-Jarez, 42270, France

Conditions

Explore the condition pages connected to this study.

NEUROENDOCRINE TUMORS